Phenotype
|
Conditions
|
Figures
|
alar plate midbrain region morphology, abnormal
|
control
|
Fig. 2
from Jászai et al., 2003
|
anatomical system quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
anterior cardinal vein absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
apoptotic process increased occurrence, abnormal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
apoptotic process occurrence, normal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
blood circulation decreased functionality, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
blood circulation disrupted, abnormal
|
standard conditions
|
Fig. 1
from Brand et al., 1996
|
blood vessel organization quality, normal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
blood vessel development process quality, normal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
blood vessel endothelial cell present, normal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
brain quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
brain vasculature dorsal region absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
branchiostegal ray 1 bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
cardiac ventricle decreased length, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
cardiac ventricle hypotrophic, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
cartilage development disrupted, abnormal
|
standard conditions
|
Fig. 8
from Sperber et al., 2008
|
cell population proliferation occurrence, normal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
cell proliferation in hindbrain disrupted, abnormal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
cell proliferation in midbrain disrupted, abnormal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
central nervous system development disrupted, abnormal
|
standard conditions
|
Fig. 6
from Komisarczuk et al., 2008
|
ceratobranchial 5 bone bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 2. ,
Fig. 4
from Gebuijs et al., 2019
|
ceratobranchial 5 tooth bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
ceratobranchial cartilage decreased amount, abnormal
|
standard conditions
|
Fig. 4
from Choe et al., 2014
|
ceratohyal bone decreased length, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
cerebellum absent, abnormal
|
standard conditions
|
Fig. 1 ,
Fig. 7
from Brand et al., 1996
|
cerebellum aplastic, abnormal
|
standard conditions
|
Fig. 9
from Heisenberg et al., 1999
Fig. 8
from Brand et al., 1996
|
cerebellum morphology, abnormal
|
control
|
Fig. 3
from Jászai et al., 2003
|
cerebellum development decreased process quality, abnormal
|
standard conditions
|
Fig. 7
from Reifers et al., 1998
|
cerebellum development disrupted, abnormal
|
standard conditions
|
Fig. 1 ,
Fig. 3
from Jászai et al., 2003
|
cleithrum bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
determination of left/right symmetry disrupted, abnormal
|
standard conditions
|
Fig. 8
from Sperber et al., 2008
|
diencephalon dorsal region dbx1b expression decreased amount, abnormal
|
control
|
Fig. 5
from Roberson et al., 2017
|
diencephalon dorsal region cxcl12b expression decreased distribution, abnormal
|
control
|
Fig. 6
from Roberson et al., 2017
|
diencephalon dorsal region ackr3b expression decreased distribution, abnormal
|
control
|
Fig. 6
from Roberson et al., 2017
|
embryonic pectoral fin morphogenesis process quality, normal
|
standard conditions
|
Fig. 11
from Reifers et al., 1998
|
embryonic retina morphogenesis in camera-type eye decreased process quality, abnormal
|
standard conditions
|
Fig. 1
from Picker et al., 2009
|
embryonic viscerocranium morphogenesis disrupted, abnormal
|
chemical treatment: dorsomorphin
|
Fig. 9
from Lovely et al., 2016
|
embryonic viscerocranium morphogenesis process quality, normal
|
control
|
Fig. 9
from Lovely et al., 2016
|
endocardium present, normal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
entopterygoid bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
ethmoid cartilage decreased length, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
fibroblast growth factor receptor signaling pathway process quality, abnormal
|
control
|
Fig. 2
from Kapsimali et al., 2011
|
forebrain ism1 expression absent, abnormal
|
standard conditions
|
Fig. 2
from Kesavan et al., 2020
|
forebrain neuron normal amount, normal
|
standard conditions
|
Fig. 6
from Lam et al., 2003
|
forebrain neuron spatial pattern, normal
|
standard conditions
|
Fig. 6
from Lam et al., 2003
|
forebrain neural rod ism1 expression absent, abnormal
|
standard conditions
|
Fig. 2
from Kesavan et al., 2020
|
head decreased size, abnormal
|
standard conditions
|
Fig. 2. ,
Fig. 3
from Gebuijs et al., 2019
|
head anterior region decreased width, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
heart decreased length, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
heart dysplastic, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
heart morphology, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
heart development process quality, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
heart rudiment decreased size, abnormal
|
standard conditions
|
Fig. 2
from Marques et al., 2008
|
hindbrain apoptotic, abnormal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
hindbrain blood vessel absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
inner ear decreased size, abnormal
|
standard conditions
|
Fig. 7
from Brand et al., 1996
Table 3
from Whitfield et al., 1996
|
inner ear has fewer parts of type otolith, abnormal
|
standard conditions
|
Table 3
from Whitfield et al., 1996
|
inner ear quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
intermediate mesoderm differentiated, normal
|
standard conditions
|
Fig. 10
from Reifers et al., 1998
|
intersegmental vessel absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
locus ceruleus development disrupted, abnormal
|
standard conditions
|
Fig. 6
from Guo et al., 1999
|
locus coeruleus absent, abnormal
|
standard conditions
|
Fig. 6
from Guo et al., 1999
|
locus coeruleus aplastic, abnormal
|
control
|
Fig. 4
from Jászai et al., 2003
|
locus coeruleus neuron decreased amount, abnormal
|
standard conditions
|
Fig. 6
from Lam et al., 2003
|
Meckel's cartilage decreased length, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
Meckel's cartilage-palatoquadrate cartilage joint decreased width, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
mesoderm anterior region has2 expression absent, abnormal
|
chemical treatment: SU5402
|
Fig. 8
from McCarthy et al., 2016
|
midbrain morphology, abnormal
|
control
|
Fig. 2
from Jászai et al., 2003
|
midbrain quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
midbrain hindbrain boundary absent, abnormal
|
standard conditions
|
Fig. 1 ,
Fig. 7
from Brand et al., 1996
|
midbrain hindbrain boundary aplastic, abnormal
|
standard conditions
|
Fig. 1 ,
Fig. 3 ,
Fig. 4
from Jászai et al., 2003
Fig. 8
from Brand et al., 1996
|
midbrain hindbrain boundary morphology, abnormal
|
standard conditions
|
Fig. 5
from Nechiporuk et al., 2007
|
midbrain hindbrain boundary physical object quality, abnormal
|
standard conditions
|
Fig. 8
from Reifers et al., 1998
|
midbrain hindbrain boundary quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
midbrain hindbrain boundary blood vessel absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
midbrain hindbrain boundary neural rod ism1 expression absent, abnormal
|
standard conditions
|
Fig. 2
from Kesavan et al., 2020
|
midbrain hindbrain boundary neural rod morphology, abnormal
|
control
|
Fig. 1 ,
Fig. 2
from Jászai et al., 2003
|
midbrain neural rod increased thickness, abnormal
|
standard conditions
|
Fig. 7
from Brand et al., 1996
|
midbrain neural rod morphology, abnormal
|
control
|
Fig. 2
from Jászai et al., 2003
|
midbrain neural rod prominent, abnormal
|
standard conditions
|
Fig. 7
from Brand et al., 1996
|
midbrain-hindbrain boundary development decreased process quality, abnormal
|
standard conditions
|
Fig. 7 ,
Fig. 8
from Reifers et al., 1998
|
midbrain-hindbrain boundary development disrupted, abnormal
|
standard conditions
|
Fig. 5
from Nechiporuk et al., 2007
Fig. 1 ,
Fig. 2 ,
Fig. 3 ,
Fig. 4
from Jászai et al., 2003
|
myocardium present, normal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
nervous system quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
neurocranium posterior region absent, abnormal
|
chemical treatment: SU5402
|
Fig. 8
from McCarthy et al., 2016
|
notochord bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
opercle bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
optic cup physical object quality, abnormal
|
standard conditions
|
Fig. 1
from Picker et al., 2009
|
optic tectum apoptotic, abnormal
|
standard conditions
|
Fig. 5
from Jászai et al., 2003
|
optic tectum increased size, abnormal
|
standard conditions
|
Fig. 1
from Jászai et al., 2003
Fig. 1 ,
Fig. 7 ,
Fig. 8
from Brand et al., 1996
|
optic tectum blood vessel absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
oral epithelium has fewer parts of type taste bud, abnormal
|
control
|
Fig. 2
from Kapsimali et al., 2011
|
otic placode physical object quality, abnormal
|
standard conditions
|
Fig. 4
from Mackereth et al., 2005
|
otic placode formation process quality, abnormal
|
standard conditions
|
Fig. 2
from Kwon et al., 2009
|
otic vesicle agenesis, abnormal
|
chemical treatment: SB 431542
|
Fig. 1
from Kwon et al., 2009
|
otic vesicle hmx3a expression decreased amount, abnormal
|
standard conditions
|
Fig. 3
from Adamska et al., 2000
|
otic vesicle decreased size, abnormal
|
standard conditions
|
Fig. 3
from Maier et al., 2014
Fig. 1
from Kwon et al., 2009
Fig. 5
from Hans et al., 2007
Fig. 4 ,
Fig. 7
from Mackereth et al., 2005
|
otic vesicle has fewer parts of type otolith, abnormal
|
standard conditions
|
Fig. 7
from Mackereth et al., 2005
|
otic vesicle malformed, abnormal
|
standard conditions
|
Fig. 1
from Kwon et al., 2009
|
otic vesicle formation process quality, abnormal
|
chemical treatment: SB 431542
|
Fig. 1
from Kwon et al., 2009
|
otic vesicle morphogenesis process quality, abnormal
|
standard conditions
|
Fig. 4 ,
Fig. 7
from Mackereth et al., 2005
|
otolith bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
otolith organ has fewer parts of type otolith, abnormal
|
standard conditions
|
Fig. 7
from Brand et al., 1996
|
parasphenoid bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 2. ,
Fig. 4
from Gebuijs et al., 2019
|
pectoral fin bud morphology, normal
|
standard conditions
|
Fig. 11
from Reifers et al., 1998
|
pharyngeal arch morphology, abnormal
|
standard conditions
|
Fig. 4
from Plaster et al., 2007
|
pharyngeal arch blood vessel absent, abnormal
|
standard conditions
|
Fig. 1
from Reifers et al., 2000
|
pharyngeal arch 3-7 morphology, abnormal
|
standard conditions
|
Fig. 8
from Sperber et al., 2008
|
pharyngeal arch 3-7 skeleton disorganized, abnormal
|
standard conditions
|
Fig. 4
from Plaster et al., 2007
|
pharyngeal arch 3-7 skeleton quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
pharyngeal arch cartilage morphology, abnormal
|
chemical treatment: dorsomorphin
|
Fig. 9
from Lovely et al., 2016
|
pharyngeal pouch decreased amount, abnormal
|
standard conditions
|
Fig. 4
from Choe et al., 2014
|
post-vent region curved ventral, abnormal
|
standard conditions
|
Table 1
from Brand et al., 1996
|
post-vent region morphology, normal
|
standard conditions
|
Fig. 5
from Plaster et al., 2007
|
post-vent region mesoderm morphology, abnormal
|
chemical treatment: trichostatin A
|
Fig. 8
from Plaster et al., 2007
|
post-vent region mesoderm morphology, normal
|
standard conditions
|
Fig. 5
from Plaster et al., 2007
|
posterior macula decreased size, abnormal
|
standard conditions
|
Fig. 3
from Maier et al., 2014
|
posterior macula has fewer parts of type hair cell, abnormal
|
standard conditions
|
Fig. 3
from Maier et al., 2014
|
retina development in camera-type eye disrupted, abnormal
|
standard conditions
|
Fig. 11
from McMahon et al., 2009
|
retinal ganglion cell axon guidance disrupted, abnormal
|
standard conditions
|
Table 1
from Brand et al., 1996
|
rhombomere 1 morphology, abnormal
|
control
|
Fig. 4
from Jászai et al., 2003
|
rhombomere 3 decreased thickness, abnormal
|
control
|
Fig. 4
from Jászai et al., 2003
|
rhombomere 5 decreased thickness, abnormal
|
control
|
Fig. 4
from Jászai et al., 2003
|
rostrocaudal neural tube patterning disrupted, abnormal
|
control
|
Fig. 4
from Jászai et al., 2003
|
segmental plate ab2-mapk labeling decreased amount, abnormal
|
standard conditions
|
Fig. S1
from Akiyama et al., 2014
|
segmental plate decreased size, abnormal
|
chemical treatment: trichostatin A
|
Fig. 8
from Plaster et al., 2007
|
semicircular canal truncated, abnormal
|
standard conditions
|
Fig. 7
from Brand et al., 1996
|
sensory system quality, abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|
somite uncx4.1 expression increased distribution, abnormal
|
standard conditions
|
Fig. 8
from Nittoli et al., 2019
|
somite uncx expression increased distribution, abnormal
|
standard conditions
|
Fig. 8
from Nittoli et al., 2019
|
somite poorly differentiated, abnormal
|
standard conditions
|
Fig. 10
from Reifers et al., 1998
|
somite size, normal
|
control
|
Fig. 4
from Kok et al., 2010
|
somite development decreased process quality, abnormal
|
standard conditions
|
Fig. 10
from Reifers et al., 1998
|
somitogenesis process quality, abnormal
|
standard conditions
|
Fig. S1
from Akiyama et al., 2014
|
statoacoustic (VIII) ganglion hmx3a expression absent, abnormal
|
standard conditions
|
Fig. 3
from Adamska et al., 2000
|
taste bud formation decreased process quality, abnormal
|
control
|
Fig. 2
from Kapsimali et al., 2011
|
tegmentum morphology, abnormal
|
standard conditions
|
Fig. 8
from Brand et al., 1996
|
thyroid primordium decreased size, abnormal
|
standard conditions
|
Fig. 6
from Wendl et al., 2007
|
whole organism dlx2a expression absent, abnormal
|
standard conditions
|
Fig. 6.
from Gebuijs et al., 2019
|
whole organism col9a1b expression decreased amount, abnormal
|
standard conditions
|
Fig. 5
from Gebuijs et al., 2019
|
whole organism col1a1a expression decreased amount, abnormal
|
standard conditions
|
Fig. 5
from Gebuijs et al., 2019
|
whole organism sp7 expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Gebuijs et al., 2019
|
whole organism fgf8a expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Gebuijs et al., 2019
|
whole organism runx2a expression increased amount, abnormal
|
standard conditions
|
Fig. 5,
Fig. 6.
from Gebuijs et al., 2019
|
whole organism nkx3-2 expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Gebuijs et al., 2019
|
whole organism dlx2a expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Gebuijs et al., 2019
|
whole organism lacks all parts of type midbrain hindbrain boundary, abnormal
|
standard conditions
|
Fig. 7
from Reifers et al., 1998
|
whole organism lacks all parts of type cerebellum, abnormal
|
standard conditions
|
Fig. 7
from Reifers et al., 1998
|
whole organism lethal (sensu genetics), abnormal
|
standard conditions
|
Fig. for (ti282a)
from Phenotype Annotation (1994-2006)
|